Nat Commun . Development of A4 Antibody for Detection of Neuraminidase I223R/H275Y-associated Antiviral Multidrug-Resistant Influenza Virus

[tetano]

Nat Commun


. 2020 Jul 9;11(1):3418.
doi: 10.1038/s41467-020-17246-w.
Development of A4 Antibody for Detection of Neuraminidase I223R/H275Y-associated Antiviral Multidrug-Resistant Influenza Virus


Kyeonghye Guk ^{1 2} , Hyeran Kim ¹ , Miyeon Lee ³ , Yoon-Aa Choi ⁴ , Seul Gee Hwang ^{1 2} , Gaon Han ^{1 2} , Hye-Nan Kim ¹ , Hongki Kim ¹ , Hwangseo Park ⁵ , Dongeun Yong ⁶ , Taejoon Kang ⁷ , Eun-Kyung Lim ^{8 9} , Juyeon Jung ^{10 11}



Affiliations

• PMID: 32647286
• DOI: 10.1038/s41467-020-17246-w

Abstract

The emergence and spread of antiviral drug-resistant viruses have been a worldwide challenge and a great concern for patient care. We report A4 antibody specifically recognizing and binding to the mutant I223R/H275Y neuraminidase and prove the applicability of A4 antibody for direct detection of antiviral multidrug-resistant viruses in various sensing platforms, including naked-eye detection, surface-enhanced Raman scattering-based immunoassay, and lateral flow system. The development of the A4 antibody enables fast, simple, and reliable point-of-care assays of antiviral multidrug-resistant influenza viruses. In addition to current influenza virus infection testing methods that do not provide information on the antiviral drug-resistance of the virus, diagnostic tests for antiviral multidrug-resistant viruses will improve clinical judgment in the treatment of influenza virus infections, avoid the unnecessary prescription of ineffective drugs, and improve current therapies.